CS
AUPH icon

Credit Suisse’s Aurinia Pharmaceuticals AUPH Stock Holding History

Credit Suisse’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$1.1M Hold
219,468
– – ﹤0.01% 2207
2023
Q4 		$1.97M Buy
219,468
+55,597
+34% +$458K ﹤0.01% 1888
2023
Q3 		$1.27M Buy
163,871
+4,081
+3% +$39.9K ﹤0.01% 2136
2023
Q2 		$1.55M Buy
159,790
+34,944
+28% +$363K ﹤0.01% 2096
2023
Q1 		$1.37M Buy
124,846
+8,580
+7% +$75.6K ﹤0.01% 2116
2022
Q4 		$502K Sell
116,266
-24,823
-18% -$144K ﹤0.01% 2768
2022
Q3 		$1.06M Buy
141,089
+46,328
+49% +$401K ﹤0.01% 2289
2022
Q2 		$953K Sell
94,761
-9,338
-9% -$104K ﹤0.01% 2423
2022
Q1 		$1.29M Sell
104,099
-177,048
-63% -$2.74M ﹤0.01% 2371
2021
Q4 		$6.43M Buy
281,147
+199,200
+243% +$4.72M ﹤0.01% 1825
2021
Q3 		$1.81M Sell
81,947
-16,028
-16% -$254K ﹤0.01% 2887
2021
Q2 		$1.27M Sell
97,975
-68,108
-41% -$868K ﹤0.01% 3197
2021
Q1 		$2.16M Buy
166,083
+51,105
+44% +$741K ﹤0.01% 2757
2020
Q4 		$1.59M Buy
114,978
+17,892
+18% +$260K ﹤0.01% 3002
2020
Q3 		$1.43M Buy
97,086
+31,059
+47% +$450K ﹤0.01% 2673
2020
Q2 		$1.07M Sell
66,027
-4,065
-6% -$65.1K ﹤0.01% 2853
2020
Q1 		$1.02M Buy
70,092
+20,734
+42% +$366K ﹤0.01% 2634
2019
Q4 		$1M Buy
49,358
+26,552
+116% +$245K ﹤0.01% 3114
2019
Q3 		$121K Sell
22,806
-1,497
-6% -$9.06K ﹤0.01% 3947
2019
Q2 		$160K Buy
24,303
+4,194
+21% +$26.7K ﹤0.01% 3887
2019
Q1 		$130K Buy
20,109
+2,894
+17% +$19.2K ﹤0.01% 3823
2018
Q4 		$118K Sell
17,215
-1,812
-10% -$10.4K ﹤0.01% 3749
2018
Q3 		$127K Sell
19,027
-3,851
-17% -$21.6K ﹤0.01% 3705
2018
Q2 		$128K Sell
22,878
-5,422
-19% -$30.2K ﹤0.01% 3811
2018
Q1 		$147K Buy
28,300
+9,021
+47% +$48.3K ﹤0.01% 3749
2017
Q4 		$87K Buy
+19,279
New +$107K ﹤0.01% 3852

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse's AUPH Position: Q1 2024 in Review

Credit Suisse held its Aurinia Pharmaceuticals (AUPH) position steady in Q1 2024 at 219,468 shares worth $1.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2207.

Credit Suisse first reported a position in AUPH in Q4 2017 and has held it in 26 quarters since. The position peaked at $6.43M in Q4 2021. 179 funds tracked by Wall St. Rank hold AUPH as of Q1 2024.

  • Credit Suisse held 219,468 shares of Aurinia Pharmaceuticals worth $1.1M as of Q1 2024.
  • Credit Suisse left its Aurinia Pharmaceuticals share count unchanged in Q1 2024.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2207 holding.
  • Credit Suisse first reported a position in Aurinia Pharmaceuticals in Q4 2017 and has held it in 26 quarters since.
  • Credit Suisse's Aurinia Pharmaceuticals position peaked at $6.43M in Q4 2021.
  • 179 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.